Photys TherapeuticsPartnershipPhotys Therapeutics inks deal with Novo NordiskLatest NewsNovo Nordiks has licenced Photys Therapeutics PHICS platform to target a single cardiometabolic target. Photys got US$186m upfront. Read more 18 December 2024 https://european-biotechnology.com/wp-content/uploads/2024/12/Photys-GRAPHIC-v3-1.jpg 1010 1748 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2024-12-18 16:40:592024-12-18 16:40:59Photys Therapeutics inks deal with Novo Nordisk